Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| β-Interleukin I (163-171), human acetate | β-Interleukin I (163-171), human acetate is a peptide involved in the regulation of immune responses, inflammatory reactions, and hematopoiesis. Synonyms: H-Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys-OH.CH3CO2H; L-valyl-L-glutaminyl-glycyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-asparagyl-L-alpha-aspartyl-L-lysine acetic acid. Grades: ≥95%. CAS No. 2763583-73-7. Molecular formula: C41H68N12O21. Mole weight: 1065.05. |  |
| Interleukin-1β Fragment 163-171 human | Interleukin-1β Fragment 163-171 human is a peptide involved in the regulation of immune responses, inflammatory reactions, and hematopoiesis. Synonyms: H-Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys-OH; L-valyl-L-glutaminyl-glycyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-asparagyl-L-alpha-aspartyl-L-lysine; L-Lysine, L-valyl-L-glutaminylglycyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-α-aspartyl-; L-Lysine, N2-[N-[N2-[N-[N-[N-[N-(N2-L-valyl-L-glutaminyl)glycyl]-L-α-glutamyl]-L-α-glutamyl]-L-seryl]-L-asparaginyl]-L-α-aspartyl]-; L-Valyl-L-glutaminylglycyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-α-aspartyl-L-lysine; Sclavo peptide; β-Interleukin I (163-171), human. Grades: 95%. CAS No. 106021-96-9. Molecular formula: C39H64N12O19. Mole weight: 1004.99. | |
| Asiaticoside | Antibacterial. Human collagen I synthesis inducer. Anti-wrinkle activity. Shows wound healing activity. Enhances normal human skin cell migration, attachment and growth. Suppresses collagen expression and TGF-beta/Smad signaling by inducing Smad7 and inhibiting TGF-betaRI and TGF-betaRII. Anti-inflammatory. Anti-gastric ulcer. Mitogen-activated protein kinases (MAPKs), nuclear factor-kappaB (NF-kappaB), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS; NOSII) expression, production of serum tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6) inhibitor. Apoptosis inducer in cancer cells. Enhances antitumor activity of vincristine in cancer cells. Might be useful in cancer chemotherapy. Anxiolytic. Antidepressant-like activity. Hepatoprotective effects. CYP2C19 and CYP3A4 inhibitor. Neuroprotective. Antileishmanial activity. cPLA2 and sPLA2 inhibitor. Group: Biochemicals. Alternative Names: Blastostimulina, Centelase, Emdecassol, Madecassol, Marticassol, FK1080, BRN 0078195, NSC 166062. Grades: Highly Purified. CAS No. 16830-15-2. Pack Sizes: 10mg, 50mg. Molecular Formula: C48H78O19. US Biological Life Sciences. |  Worldwide |
| Avizakimab | Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21 [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: BOS161721. CAS No. 2229685-51-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99451. |  |
| Bermekimab | Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: MABp1. CAS No. 1401965-15-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99246. | |
| Brodalumab | Brodalumab (AMG 827) is a human anti- interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: AMG 827; KHK4827. CAS No. 1174395-19-7. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9925. | |
| Brodalumab | Brodalumab is a human monoclonal antibody that binds to the interleukin-17 receptor and inhibits the binding of IL-17 to its receptor. Brodalumab has been approved for the treatment of moderate to severe plaque psoriasis. Synonyms: Siliq; Kyntheum; AMG-827; KHK-4827; anti-IL17RA. CAS No. 1174395-19-7. | |
| Butein | Butrin, isobutrin, and butein from medicinal plant Butea monosperma selectively inhibit nuclear factor-κB in activated human mast cells: suppression of tumor necrosis factor-α, interleukin (IL)-6, and IL-8. Anti-inflammatory agent. Group: Biochemicals. Alternative Names: (2E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one; 2',3,4,4'-Tetrahydroxychalcone. Grades: Highly Purified. CAS No. 487-52-5. Pack Sizes: 20mg, 50mg, 100mg, 250mg. Molecular Formula: C??H??O?, Molecular Weight: 272.25. US Biological Life Sciences. | Worldwide |
| caspase-1 | From mammalian monocytes. This enzyme is part of the family of inflammatory caspases, which also includes caspase-4 (EC 3.4.22.57) and caspase-5 (EC 3.4.22.58) in humans and caspase-11 (EC 3.4.22.64), caspase-12, caspase-13 and caspase-14 in mice. Contains a caspase-recruitment domain (CARD) in its N-terminal prodomain, which plays a role in procaspase activation. Cleaves pro-interleukin-1β (pro-IL-1β) to form mature IL-1β, a potent mediator of inflammation. Also activates the proinflammatory cytokine, IL-18, which is also known as interferon-γ-inducing factor. Inhibited by Ac-Tyr-Val-Ala-Asp-CHO. Caspase-11 plays a critical role in the activation of caspase-1 in mi...proteinase; ICE. Enzyme Commission Number: EC 3.4.22.36. CAS No. 122191-40-6. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4211; caspase-1; EC 3.4.22.36; 122191-40-6; interleukin 1β-converting enzyme; protease VII; protease A; interleukin 1β precursor proteinase; interleukin 1 converting enzyme; interleukin 1β-converting endopeptidase; interleukin-1β convertase; interleukin-1β converting enzyme; interleukin-1β precursor proteinase; prointerleukin 1β protease; precursor interleukin-1β converting enzyme; pro-interleukin 1β proteinase; ICE. Cat No: EXWM-4211. |  |
| caspase-11 | This murine enzyme is part of the family of inflammatory caspases, which also includes caspase-1 (EC 3.4.22.36), caspase-4 (EC 3.4.22.57) and caspase-5 (EC 3.4.22.58) in humans and caspase-12, caspase-13 and caspase-14 in mice. Contains a caspase-recruitment domain (CARD) in its N-terminal prodomain, which plays a role in procaspase activation. Like caspase-5, but unlike caspase-4, this enzyme can be induced by lipopolysaccharide. This enzyme not only activates caspase-1, which is required for the maturation of proinflammatory cytokines such as interleukin-1β (IL-1β) and IL-18, but it also activates caspase-3 (EC 3.4.22.56), which leads to cellular apoptosis under pathological conditions. Belongs in peptidase family C14. Group: Enzymes. Synonyms: CASP-11. Enzyme Commission Number: EC 3.4.22.64. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4240; caspase-11; EC 3.4.22.64; CASP-11. Cat No: EXWM-4240. | |
| Caspase-1 from Human, Recombinant | Caspase 1/Interleukin-1 converting enzyme is an enzyme that proteolytically cleaves other proteins, such as the precursor forms of the inflammatory cytokines interleukin 1β and interleukin 18, into active mature peptides. Caspase 1 has been shown to induce cell necrosis or pyroptosis and may function in various developmental stages. Studies of a similar protein in mouse suggest a role in the pathogenesis of Huntington's disease. Alternative splicing of the gene results in five transcript variants encoding distinct isoforms. Recent studies implicated caspase 1 in promoting CD4 T-cell death and inflammation by HIV, two signature events that fuel HIV disease progression to AIDS. Recombinant, human caspase-1 fused at the n-terminus to a hisotag sequence and expressed in e. coli useful for the study of enzyme regulation, cleavage of target substrates, and inhibitor screening. Group: Enzymes. Synonyms: CASP1; ICE; IL1BC; P45; Caspase 1; Interleukin-1; IL-1β Converting Enzyme. Purity: >90% by SDS-PAGE. Caspase-1. Mole weight: 10 kDa and 20 kDa. Activity: >25,000 units/mg protein. Storage: < -70°C; Avoid freeze/thaw. Form: Liquid. Source: E. coli. Species: Human. CASP1; ICE; IL1BC; P45; Caspase 1; Interleukin-1; IL-1β Converting Enzyme. Cat No: NATE-0813. | |
| caspase-4 | This enzyme is part of the family of inflammatory caspases, which also includes caspase-1 (EC 3.4.22.36) and caspase-5 (EC 3.4.22.58) in humans and caspase-11 (EC 3.4.22.64), caspase-12, caspase-13 and caspase-14 in mice. Contains a caspase-recruitment domain (CARD) in its N-terminal prodomain, which plays a role in procaspase activation. The enzyme is able to cleave itself and the p30 caspase-1 precursor, but, unlike caspase-1, it is very inefficient at generating mature interleukin-1β (IL-1β) from pro-IL-1&beta. Both this enzyme and caspase-5 can cleave pro-caspase-3 to release the small subunit (p12) but not the large subunit (p17). The caspase-1 inhibitor Ac-Tyr-Val-Ala-Asp-CHO can also inhibit this enzyme, but more slowly. Belongs in peptidase family C14. Group: Enzymes. Synonyms: ICErelII; ICErel-II; Ich-2; transcript X; TX; TX protease; caspase 4; CASP-4. Enzyme Commission Number: EC 3.4.22.57. CAS No. 182762-08-9. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4232; caspase-4; EC 3.4.22.57; 182762-08-9; ICErelII; ICErel-II; Ich-2; transcript X; TX; TX protease; caspase 4; CASP-4. Cat No: EXWM-4232. | |
| caspase-5 | This enzyme is part of the family of inflammatory caspases, which also includes caspase-1 (EC 3.4.22.36) and caspase-4 (EC 3.4.22.57) in humans and caspase-11 (EC 3.4.22.64), caspase-12, caspase-13 and caspase-14 in mice. Contains a caspase-recruitment domain (CARD) in its N-terminal prodomain, which plays a role in procaspase activation. The enzyme is able to cleave itself and the p30 caspase-1 precursor, but is very inefficient at generating mature interleukin-1β (IL-1β) from pro-IL-1&beta. Both this enzyme and caspase-4 can cleave pro-caspase-3 to release the small subunit (p12) but not the large subunit (p17). Unlike caspase-4, this enzyme can be induced by lipopolysaccharide. Belongs in peptidase family C14. Group: Enzymes. Synonyms: ICErel-III; Ich-3; ICH-3 protease; transcript Y; TY; CASP-5. Enzyme Commission Number: EC 3.4.22.58. CAS No. 192465-11-5. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4233; caspase-5; EC 3.4.22.58; 192465-11-5; ICErel-III; Ich-3; ICH-3 protease; transcript Y; TY; CASP-5. Cat No: EXWM-4233. | |
| Celastramycin A | Celastramycin A is a bioactive compound isolated from endophytic bacteria. Celastramycin A exhibited high activity against a series of multiresistent bacteria and mycobacteria. It inhibits the growth of Gram-positive bacteria and mycobacteria with minimal inhibitory concentration (MIC). Celastramycin A suppresses the production of interleukin-8 in human umbilical vein endothelial cells as stimulated by tumor necrosis factor-α with IC50 of 0.01 μg/ml. It can also be used as a lead compound for novel immunosuppressive agents. Grades: ≥97%. CAS No. 491600-94-3. Molecular formula: C17H18Cl3NO3. Mole weight: 390.69. | |
| CJ-14877 | It is originally isolated from Marasmiellus sp. CL21624. CJ-14877 inhibited human blood interleukin-1β (IL-1β) production induced by lipoglycan (LPS) with an IC50 of 0.1 μmol/L. Synonyms: 2-Pyridinecarboxylic acid, 5-[(1S,2S)-1,2-dihydroxypropyl]-, methyl ester. Molecular formula: C10H13NO4. Mole weight: 211.21. | |
| CJ-14897 | It is originally isolated from Marasmiellus sp. CL21624. CJ-14897 inhibited human blood interleukin-1β (IL-1β) production induced by lipoglycan (LPS) with an IC50 of 0.059 μmol/L. Synonyms: (+)-CJ-14897; 2-Pyridinecarboxylic acid, 5-((1S,2S)-2-(acetyloxy)-1-hydroxypropyl)-, methyl ester; UNII-10M04QP59K. CAS No. 377755-95-8. Molecular formula: C12H15NO5. Mole weight: 253.25. | |
| Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Zenapax; Ro 24-7375. CAS No. 152923-56-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-108738. | |
| Dinutuximab | Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: APN-311. CAS No. 1363687-32-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9933. | |
| Elsilimomab | Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6) , with a K D of 22 pM and an IC 50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) [1] [2] [3]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody. CAS No. 468715-71-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99287. | |
| Elubrixin | Elubrixin is a interleukin 8 inhibitor and CXCR2 selective antagonist. It is potentially useful for Inflammatory bowel disease therapies. It inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. It may be an effective agent in neutrophil-predominant diseases. It was developed by GlaxoSmithKline and was in clinic phase 2 trials, but now it is terminated. Uses: Elubrixin is potentially useful for inflammatory bowel disease therapies. it may be an effective agent in neutrophil-predominant diseases. Synonyms: 1-(2-Chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea;SB-656933;SB656933;SB-656933-AAF;SB-656933-AAA;SB656933AAA;SB656933AAF;1-(4-Chloro-2-hydroxy-3-(piperazin-1-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea. Grades: 98%. CAS No. 688763-64-6. Molecular formula: C17H17Cl2FN4O4S. Mole weight: 463.30. | |
| Etanercept | Etanercept inhibits in vitro the activity of human TNF and is efficacious in many in vivo models of inflammation, including arthritis. Etanercept competitively inhibits the binding of both TNF-α and TNF-β (lymphotoxin-α) to cell surface TNF receptors, rendering TNF biologically inactive. It also modulates indirectly different biological responses that are induced or regulated by TNF, such as the expression of adhesion molecules E-selectin and to a lesser extent intercellular adhesion molecule 1 (ICAM-1), the production of interleukin-6 (IL-6) and matrix metalloproteinase 3 (MMP-3) (stromelysin), as well as IL1. Synonyms: 1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment); TNFR-Fc fusion protein; Etanercept; Embrel; Enbrel; rhu-TNFR-Fc. Grades: 95%. CAS No. 185243-69-0. Molecular formula: C2224H3472N618O701S36. | |
| Fezakinumab | Fezakinumab is a human monoclonal antibody that targets interleukin-22. Fezakinumab has been developed for the treatment of psoriasis and rheumatoid arthritis. Synonyms: ILV 094; ILV-094; ILV094. CAS No. 1007106-86-6. | |
| FSL-1-FLAG | Lipopeptide FSL-1, synthesized on the basis of the N-terminal structure of M. salivarium lipoprotein, can induce ICAM-1 expression on the surface of human gingival fibroblasts. In addition, it induces the production of monocyte chemoattractant protein 1, interleukin-6 (IL-6), and IL-8. It activates macrophages to produce tumor necrosis factor-alpha. Synonyms: Fibroblast Stimulating Lipopeptide 1 FLAG-tag; H-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-Gly-Asp-Pro-Lys-His-Pro-Lys-Ser-Phe-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OH; L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-α-aspartyl-L-prolyl-L-lysyl-L-histidyl-L-prolyl-L-lysyl-L-seryl-L-phenylalanyl-L-α-aspartyl-L-tyrosyl-L-lysyl-L-α-aspartyl-L-α-aspartyl-L-α-aspartyl-L-α-aspartyl-. Grades: ≥95%. CAS No. 2243206-97-3. Molecular formula: C125H198N24O37S. Mole weight: 2661.15. | |
| IL2 | Recombinant human IL - 2; Interleukin-2 is a secreted cytokine, also called IL-2. Aldesleukin (IL-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Synonyms: Iloprost R-isomer; 74843-13-3; 16(R)-Iloprost; 16-(R)-Iloprost; UNII-AHG2128QW6; AHG2128QW6; (5E)-5-((3aS,4R,5R,6aS)-5-Hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; Pentanoic acid, 5-((3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-, (5E)-; (5e)-5-[(3as,4r,5r,6as)-5-Hydroxy-4-[(1e,3s,4r)-3-Hydroxy-4-Methyloct-1-En-6-Yn-1-Yl]hexahydropentalen-2(1h)-Ylidene]pentanoic Acid; IL2; SCHEMBL21509107; AKOS040755122; PD021248; Q27273925; 5-((3AS,4R,5R,6aS,E)-5-hydroxy-4-((3S,4R,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid. Molecular formula: C22H32O4. Mole weight: 360.5. | |
| Il-6(88-121)(human) | Il-6(88-121)(human). Uses: Designed for use in research and industrial production. Additional or Alternative Names: H-ILE-ILE-THR-GLY-LEU-LEU-GLU-PHE-GLU-VAL-TYR-LEU-GLU-TYR-LEU-GLN-ASN-ARG-PHE-GLU-SER-SER-GLU-GLU-GLN-ALA-ARG-ALA-VAL-GLN-MET-SER-THR-LYS-OH;IL-6 (88-121) (HUMAN);INTERLEUKIN-6 (88-121) (HUMAN);interleukin-6 fragment 88-121;IL-6 (88-121);Interleukin-6. Product Category: Heterocyclic Organic Compound. CAS No. 145990-81-4. Molecular formula: C179H281N45O58S. Product ID: ACM145990814. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Imiquimod | Cell-permeable. Topical immune response modifier that displays anti-angiogenic, anti-viral and anti-inflammatory properties. Up-regulates IL-18 and down-regulates MMP-9 through recognition of Toll-like receptor 7 (TLR7) and subsequent activation of MyD88-dependent pathway. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB. Caspase-3 activator that directly induces procaspase-3 cleavage. Anti-cancer compound. Apoptosis inducer. Antiproliferative, independent of immune system activation or function. Approved treatment for external genital warts caused by human papillomavirus infection. Group: Biochemicals. Alternative Names: 1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; R-837; S-26308. Grades: Highly Purified. CAS No. 99011-02-6. Pack Sizes: 100mg, 250mg, 500mg, 1g. Molecular Formula: C14H16N4. US Biological Life Sciences. | Worldwide |
| ixekizumab | Ixekizumab is a humanized monoclonal antibody that inhibits interleukin 17A (IL-17A). It was approved by FDA for the treatment of moderate to severe plaque psoriasis in adult patients. Uses: The treatment of plaque psoriasis. Synonyms: LY2439821; Taltz. Grades: ≥98%. CAS No. 1143503-69-8. Molecular formula: C6492H10012N1728O2028S46. Mole weight: 146200. | |
| Ixekizumab | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A ( K D <3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: LY2439821. CAS No. 1143503-69-8. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9924. | |
| kallikrein 13 | The enzyme is specific for prorenin from the mouse submandibular gland, as prorenin from the mouse kidney (Ren1) and human prorenin are not substrates. Site-directed mutagenesis studies have shown that the enzyme will also cleave prorenin when Lys-Arg is replaced by Arg-Arg or Gln-Arg but the rate of reaction is much slower when Lys-Lys is used. This enzyme is also able to process pro-interleukin-1β (pro-IL-1β) in mouse submandibular gland to form IL-1&beta. Belongs in peptidase family S1A. Group: Enzymes. Synonyms: KLK13; kallikrein mK13; mGK-13; mK13; mKLK13; prorenin converting enzyme 1; PRECE-1; prorenin-converting enzyme; PRECE; proteinase P. Enzyme Commission Number: EC 3.4.21.119. CAS No. 342900-44-1. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4114; kallikrein 13; EC 3.4.21.119; 342900-44-1; KLK13; kallikrein mK13; mGK-13; mK13; mKLK13; prorenin converting enzyme 1; PRECE-1; prorenin-converting enzyme; PRECE; proteinase P. Cat No: EXWM-4114. | |
| Lebrikizumab | Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 ( IL-13 ) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases [1] [2] [3]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: TNX-650. CAS No. 953400-68-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99025. | |
| L-Lysine,l-valyl-L-glutaminylglycyl-L-a-glutamyl-L-a-glutamyl-L-seryl-L-asparaginyl-l-a-aspartyl- | L-Lysine,l-valyl-L-glutaminylglycyl-L-a-glutamyl-L-a-glutamyl-L-seryl-L-asparaginyl-l-a-aspartyl-. Uses: Designed for use in research and industrial production. Additional or Alternative Names: IL-1BETA (163-171) (HUMAN);IL-1B (163-171) (HUMAN);H-VAL-GLN-GLY-GLU-GLU-SER-ASN-ASP-LYS-OH;INTERLEUKIN-1BETA FRAGMENT 163-171 HUMAN;INTERLEUKIN-1BETA (163-171) (HUMAN);INTERLEUKIN-1B (163-171) (HUMAN);BETA-INTERLEUKIN I (163-171), HUMAN;VAL-GLN-GLY-GLU-. Product Category: Heterocyclic Organic Compound. CAS No. 106021-96-9. Molecular formula: C39H64N12O19. Mole weight: 1004.99. Purity: 0.96. IUPACName: (2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-. Canonical SMILES: CC(C)C(C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)O)N. Density: 1.419g/cm³. Product ID: ACM106021969. Alfa Chemistry ISO 9001:2015 Certified. | |
| Lusvertikimab | Lusvertikimab is a humanized monoclonal antibody and interleukin-7 receptor antagonist. Synonyms: OSE-127. CAS No. 2375835-91-7. | |
| LY 255283 | LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.Antagonists of the chemotactic and inflammatory lipoxygenase product leukotriene B4 (LTB4) have been potential drug development targets for several years.1,2 The tetrazole LY255283 is a competitive antagonist of the BLT2 receptor. It displaces radiolabeled LTB4 from guinea pig lung membrane, with an IC50 of about 100nM.3 LY255283 exhibits IC50 values of ~950nM and >10uM at human recombinant BLT2 and BLT1 receptors, respectively.4 LY255283 inhibits eosinophil chemotaxis by 80% at a concentration of 10uM, and inhibits the binding of radiolabeled LTB4 to eosinophil membranes with an IC50 of 260nM.1. Group: Biochemicals. Alternative Names: 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]-ethanone. Grades: Highly Purified. CAS No. 117690-79-6. Pack Sizes: 10mg, 25mg. Molecular Formula: C19H28N4O3, Molecular Weight: 360.5. US Biological Life Sciences. | Worldwide |
| Mepolizumab | Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 ( IL-5 ), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: SB 240563. CAS No. 196078-29-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9945. | |
| Mepolizumab (anti-IL5) | Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 ( IL-5 ), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 196078-29-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9945A. | |
| Mirikizumab | Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 ( IL-23 ). Mirikizumab binds to human and monkey IL-23 with high affinity, with K d values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R , Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: LY-3074828. CAS No. 1884201-71-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99737. | |
| Nemolizumab | Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 ( IL-31 ) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: CIM331. CAS No. 1476039-58-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99162. | |
| NF 546 | NF 546 is a P2Y11 agonist with pEC50 value of 6.27. It can stimulate release of interleukin-8 from human monocyte-derived dendritic cells. Synonyms: NF 546; NF546; NF-546; 4,4'-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid tetrasodium salt. Grades: ≥95% by HPLC. CAS No. 1006028-37-0. Molecular formula: C47H44N6Na4O17P4. Mole weight: 1180.74. | |
| Olokizumab | Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA) [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: CDP 6038; OKZ. CAS No. 1007223-17-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99210. | |
| Olokizumab | Olokizumab is a humanized monoclonal antibody that targets interleukin-6. Olokizumab is effective in the treatment of rheumatoid arthritis. Synonyms: CDP 6038; OKZ. CAS No. 1007223-17-7. | |
| Ordesekimab | Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti- IL-15 ( Interleukin Related ) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: AMG 714; PRV-015. CAS No. 879293-15-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99410. | |
| Pivekimab | Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate ( ADC ). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 2234335-84-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99234. | |
| R-130823 | R-130823 is a highly selective inhibitor against mitogen-activated protein kinase p38alpha (IC50=22 nM). The release of tumor necrosis factor-alpha, interleukin-1beta, -6 and -8 was inhibited in lipopolysaccharide-stimulated human blood pretreated by R-130823, with IC50 values of 0.089, 0.066, 0.95 and 0.16 microM, respectively. Synonyms: R130823; R 130823; 2-(4-Fluorophenyl)-4-(1-phenethyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole. CAS No. 321344-32-5. Molecular formula: C28H26FN3. Mole weight: 423.53. | |
| rec IL-2 (human) | Synonyms: rec Interleukin-2 (human). | |
| Resistant to Gastric Acid Inactivated Probiotics for Freckle Reduction and Skin Brighten | Inactivated probiotics have good immune functions on human body, because they are rich inlipoteichoic acid, peptidoglycan, exopolysaccharides and fatty acid. For example, EPS of bifidobacterium longum BL21 can reduce the melanin formation of B16 cells significantly. EPS (3.3 mg/ml) inhibit melanin formation rate reducing to 50%.Inactivated probiotics can't be affected by gastric acid, bile and heat. It can be used infood processing as ingredients. The products have strong induced tumor necrosisfactor, interleukin, immunoglobulin and interferon. It can promote theintestinal epithelial tissue to stimulate the intestinal bifidobacteriumproliferation, inhibiting the growth of Clostridium in the large intestine,meanwhile playing a good role of prebiotics. Inactivated probiotics as a functional ingredient can be added infood, health food and medicine. Group: Others. Synonyms: Resistant to Gastric Acid Inactivated Probiotics for Freckle Reduction and Skin Brighten. Purity: 61%~90%. Resistant to Gastric Acid Inactivated Probiotics for Freckle Reduction and Skin Brighten. Cat No: PRBT-028. | |
| reslizumab | Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. Uses: The treatment of severe asthma. Synonyms: Cinqair. CAS No. 241473-69-8. | |
| Reslizumab | Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5 , with K D values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Sch 55700. CAS No. 241473-69-8. Pack Sizes: 1 mg; 2 mg. Product ID: HY-P9949. | |
| Rilonacept | Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Arcalyst; IL 1 Trap; Interleukin 1 Trap. CAS No. 501081-76-1. Pack Sizes: 1 mg; 5 mg. Product ID: HY-108822. | |
| Ro 106-9920 | Ro 106-9920, a cell-permeable tetrazolopyridazine-phenylsulfoxide compound, is a small molecule inhibitor of NF-κB-dependent expression of TNF-α, interleukin-1β, and interleukin-6 (IC50 < 1 μM in human peripheral blood mononuclear cells). Synonyms: Ro 106-9920; Ro106-9920; Ro-106-9920; 6-(Phenylsulfinyl)tetrazolo[1,5-b]pyridazine. Grades: ≥99% by HPLC. CAS No. 62645-28-7. Molecular formula: C10H7N5OS. Mole weight: 245.26. | |
| Sarilumab | Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Anti-Human IL6Rα, Human Antibody. CAS No. 1189541-98-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9916. | |
| Satralizumab | Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1535963-91-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99112. | |
| Satralizumab | Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor. Satralizumab has been developed for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Synonyms: Enspryng. CAS No. 1535963-91-7. | |
| SB239063 | SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-alpha production. SB 239063 may be useful for the treatment of asthma and other inflammatory disorders. Uses: Protein kinase inhibitors. Synonyms: SB-239063; SB 239063. Grades: 0.98. CAS No. 193551-21-2. Molecular formula: C20H21FN4O2. Mole weight: 368.412. | |
| Secukinumab | Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: AIN457. CAS No. 1229022-83-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9927. | |
| Secukinumab | Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. Uses: The treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. Synonyms: Cosentyx. CAS No. 875356-43-7. Molecular formula: C6584H10134N1754O2042S44. Mole weight: 147944.39. | |
| Secukinumab (Anti-Human IL-17A) | Secukinumab (Anti-Human IL-17A) is a fully human anti- interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1229022-83-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9927A. | |
| Sirukumab | Sirukumab (CNTO-136) is a humanized monoclonal anti- IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6 , preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: CNTO-136. CAS No. 1194585-53-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99316. | |
| Sonelokimab | Sonelokimab is a novel trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin IL-17A, IL-17F, and human serum albumin. Sonelokimab has been used in the research of plaque psoriasis. Synonyms: ALX 0761; M 1095. CAS No. 1414386-05-2. | |
| SR1001 | Retinoic-acid-receptor-related orphan receptors (ROR) α and γ play a key role in the development of T-helper cells that produce interleukin-17 (TH17 cells), a subset of CD4+ T-cells that contribute to the inflammatory process and have been implicated in the pathology of autoimmune diseases. SR 1001 is a synthetic ligand specific for RORα and RORγ (Kis = 172 and 111 nM, respectively) that functions as an inverse agonist at these receptors. SR 1001 has been shown to suppress IL-17 promoter driven transcriptional activity by inhibiting the interaction of co-activators such as TRAP220 nuclear receptor box 2 peptide (IC50 = 117 nM) and SRC2 with RORα and RORγ as well as by increasing the recruitment of corepressors such as NCoR. At 5 μM, SR 1001 inhibits TH17 cell differentiation and IL-17A secretion in cultured splenocytes and human PBMCs. A 25 mg/kg dose of SR 1001 twice/day delays the onset and the severity of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Synonyms: SR 1001; SR-1001. Grades: >98%. CAS No. 1335106-03-0. Molecular formula: C15H13F6N3O4S2. Mole weight: 477.4. | |
| Suplatast Tosylate | Suplatast Tosylate is an antiallergic drug. Suplatast Tosylate inhibits antigen-induced histamine release from mast cells as well as IgE antibody formation. Suplatast Tosylate suppresses interleukin (IL)-4 release from T cells, however in human peripheral basophils, Suplatast Tosylate inhibited the antigen-induced release of IL-13 but not IL-4. Group: Biochemicals. Alternative Names: [3- [ [4- (3-ethoxy-2-hydroxypropoxy) phenyl] amino] -3-oxopropyl] dimethylsulfonium 4-Methyl Benzene sulfonate; (±) - [2- [4- (3-Ethoxy-2-hydroxypropoxy) phenylcarbamoyl] ethyl] dimethylsulfonium p-toluenesulfonate; IPD 1151T; Suplatast tosilate. Grades: Highly Purified. CAS No. 94055-76-2. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| tocilizumab | Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis. Actemra (tocilizumab) 162 mg syringe for subcutaneous injection and Actemra 162 mg auto-injector for subcutaneous injection was approved in Japan for the treatment of Takayasu arteritis (TAK) and giant cell arteritis (GCA), as well as its intravenous injection was approved by FDA for severe cytokine release syndrome (CRS). Uses: The treatment of rheumatoid arthritis (ra), systemic juvenile idiopathic arthritis, takayasu arteritis (tak), giant cell arteritis (gca), severe cytokine release syndrome (crs), etc. Synonyms: Anti-Human IL6R, Humanized Antibody; Actemra; R 1569; RoActemra; Atlizumab; Actemra 200; R1569; R-1569. Grades: ≥95%. CAS No. 375823-41-9. Molecular formula: C6428H9976N1720O2018S42. Mole weight: 145000. | |
| Tocilizumab | Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor ( IL-6R ) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis [1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) [4]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Anti-Human IL6R, Humanized Antibody. CAS No. 375823-41-9. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P9917. | |
| Tozorakimab | Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: MEDI-3506. CAS No. 2376858-66-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99550. | |
| Xeligekimab | Xeligekimab (GR 1501) is an anti- human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: GR 1501. CAS No. 2382921-73-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99515. | |
Our database is helping our users find suppliers everyday.
